Please login to the form below
Zaltrap
This page shows the latest Zaltrap news and features for those working in and with pharma, biotech and healthcare.
Rise in cancer therapy costs 'unsustainable' says oncologist
Saltz has been a vocal critic of cancer drug pricing for some time, and was one of the architects of MSKCC's decision three years ago not to prescribe Zaltrap ... Zaltrap was also turned down by the UK's National Institute for Health and Care Excellence
Latest news
-
Pharma condemns Cancer Drugs Fund cuts
Sanofi's Zaltrap is one of several drugs to be delisted from England's Cancer Drugs Fund. ... cancer. In the past 18 months there have been 1, 154 and 707 requests submitted to the CDF for Zaltrap and Jevtana respectively.
-
NHS names drugs to be re-evaluated for Cancer Drugs Fund
Prostate cancer. Zaltrap (aflibercept). Colorectal cancer. Takeda. Adcetris (brentuximab vedotin). Lymphoma (3 indications). .
-
Charity demands action on cancer drug prices in UK
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
-
England's Cancer Drugs Fund: Naughty or NICE?
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
-
Sex is a good trick
Recent industry news includes two stories of new products (Sanofi's Zaltrap and Bayer's Xofigo) struggling to get market access.
More from news
Approximately 3 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
The reality of real-world evidence
Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- GSK discontinues two feladilimab trials in head and neck cancer
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- Live Webinar: Advancing Human Health Through Precise Measures of Movement, Cognition & Biometrics
- Live Webinar: How to Simplify Genetics & Raise Awareness Around Orphan Diseases
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
